Affordable Access

deepdyve-link
Publisher Website

Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck.

Authors
  • Sukari, Ammar
  • Al-Hajeili, Marwan
  • Salem, Mohamed
  • Heilbrun, Lance
  • Smith, Daryn
  • Yoo, George
  • Jacobs, John R
  • Lin, Ho-Sheng
  • Kucuk, Omer
Type
Published Article
Journal
Avicenna journal of medicine
Publication Date
Jan 01, 2015
Volume
5
Issue
2
Pages
36–41
Identifiers
DOI: 10.4103/2231-0770.154195
PMID: 25878965
Source
Medline
Keywords
License
Unknown

Abstract

The biweekly GEMTAX regimen has statistically significant grade 3 and 4 adverse events and has meaningful clinical activity as a second-line treatment in patients with recurrent or metastatic SCCHN who have received prior chemotherapy. This regimen may particularly be a useful treatment option in patients who progressed in less than 6 months of concurrent chemoradiotherapy with high-dose cisplatin and/or have recurrent/metastatic platinum refractory SCCHN.

Report this publication

Statistics

Seen <100 times